ImmunityBio Targets Year-End ANKTIVA Filing for Broader Bladder Cancer Use

ImmunityBio (NASDAQ:IBRX) plans to submit an application by year-end to expand the use of its cancer treatment ANKTIVA to patients with bladder cancer who have not previously received BCG therapy, CEO Richard Adcock said at a UBS biotech conference in London.

Adcock said the company’s BCG-naïve trial met its endpoint with a p-value of 0.01, and that teams were preparing the application for submission. He did not specify the endpoint or provide detailed trial results during the presentation.

The planned submission follows a recent U.S. label expansion for ANKTIVA in BCG-unresponsive bladder cancer, Adcock said. He also outlined studies of the treatment in lung cancer, sepsis and a cancer vaccine program for people with Lynch syndrome.

Bladder Cancer Expansion

Adcock said the expanded U.S. label covers the broader BCG-unresponsive patient population, including patients with papillary disease. During the quarter he discussed, the company was selling ANKTIVA under a narrower label covering carcinoma in situ, with or without papillary tumors.

In discussing earlier BCG-naïve research, Adcock said six patients from an initial group of nine were found to remain in complete response approximately nine and a half years later, without further treatment and with their bladders intact. Two other patients had died from diseases unrelated to bladder cancer, while one could not be located, he said.

Adcock also described the company’s efforts to address a longstanding shortage of BCG, which is used alongside ANKTIVA. ImmunityBio licensed a Japanese BCG strain known as Tokyo, which it hopes to bring to the U.S. market, he said. The company has also supplied thousands of doses of a recombinant BCG strain from the Serum Institute through an expanded-access program, according to Adcock.

Lung Cancer and Sepsis Studies

ANKTIVA has been approved for lung cancer in Saudi Arabia and the United Arab Emirates, Adcock said. He pointed to the QUILT-3.055 trial in second- and third-line non-small cell lung cancer as the basis for those approvals. The company is also working on a second-line study called ResQ201A, he said.

Adcock said ANKTIVA is not yet approved for lung cancer in the United States. He argued that the drug could eventually have a broader role alongside other immunotherapies, while acknowledging that additional trials are needed to establish that potential.

In sepsis, Adcock said the U.S. Food and Drug Administration has authorized a randomized, blinded Phase 2 trial. ImmunityBio is in the initial stages of setting up sites, including Cleveland Clinic and other institutions, he said. The study will assess outcomes over 28 days.

Vaccine Program and Broader Strategy

Adcock said an NIH-run study combining N-803, the drug also known as ANKTIVA, with ImmunityBio’s Ad5 vaccine in people with Lynch syndrome has completed and is expected to report results in 2027. Lynch syndrome is an inherited condition associated with a higher risk of cancers including colon cancer.

Beyond ANKTIVA, ImmunityBio has fusion protein, DNA vaccine vector and cell therapy platforms, Adcock said. He described the company’s goal as proving whether ANKTIVA can serve as a backbone for immunotherapy across multiple diseases, an approach that remains under investigation.

About ImmunityBio (NASDAQ:IBRX)

ImmunityBio is a biotechnology company that develops immunotherapies for cancer and infectious diseases. Its research combines approaches including immune-modulating biologics, cell therapies and vaccine-based treatments, with a focus on activating the body’s natural and adaptive immune responses. The company’s lead product, Anktiva (nogapendekin alfa inbakicept-pmln), received U.S. Food and Drug Administration approval in 2024 for use with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.